Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study

被引：0
|
作者：
Gasiorek, A. [1 ]
Heydorn, A. [1 ]
Kirkeby, K. [1 ]
Key, C. [2 ]
Toubro, S. [1 ]
Schefe, L. H. [1 ]
Dahl, K. [1 ]
Hjerpsted, J. B. [1 ]
Vegge, A. [1 ]
机构：
[1] Novo Nordisk AS, Malov, Denmark
[2] ICON Plc, San Antonio Clin Res Unit, San Antonio, TX USA
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
74
引用
收藏
页码：S42 / S43
页数：2
相关论文
共 50 条
  • [1] Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide-1 Receptor Agonist
    Bucheit, John D.
    Pamulapati, Lauren G.
    Carter, Nicole
    Malloy, Kevin
    Dixon, Dave L.
    Sisson, Evan M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (01) : 10 - 18
  • [2] A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
    Griffith, David A.
    Edmonds, David J.
    Fortin, Jean-Philippe
    Kalgutkar, Amit S.
    Kuzmiski, J. Brent
    Loria, Paula M.
    Saxena, Aditi R.
    Bagley, Scott W.
    Buckeridge, Clare
    Curto, John M.
    Derksen, David R.
    Dias, Joao M.
    Griffor, Matthew C.
    Han, Seungil
    Jackson, V. Margaret
    Landis, Margaret S.
    Lettiere, Daniel
    Limberakis, Chris
    Liu, Yuhang
    Mathiowetz, Alan M.
    Patel, Jayesh C.
    Piotrowski, David W.
    Price, David A.
    Ruggeri, Roger B.
    Tess, David A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (12) : 8208 - 8226
  • [3] Glucagon-like peptide-1 receptor agonists and their effects on weight reduction
    Shin, Shyi-Jang
    JOURNAL OF DIABETES INVESTIGATION, 2012, 3 (06) : 490 - 491
  • [4] Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
    Holst, Jens Juul
    LANCET, 2019, 394 (10192): : 4 - 6
  • [5] PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE
    Al-Kawas, Firas
    Anderson, Michelle Ann
    Enns, Robert
    Wilson, Timothy H.
    Johnson, Susan
    Mallory, Jason M.
    ENDOCRINE PRACTICE, 2019, 25 (07) : 698 - 716
  • [6] Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
    Raccah, Denis
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (02) : 227 - 236
  • [7] Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity
    Yao, Zhihong
    Wang, Chen
    Zhu, Qianqian
    Sun, Lidan
    Zhou, Qiang
    Han, Jing
    Wang, Wenxi
    Bhawal, Ruchika
    PEPTIDES, 2023, 162
  • [8] Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906
    Jungnik, Arvid
    Martinez, Jorge Arrubla
    Plum-Moerschel, Leona
    Kapitza, Christoph
    Lamers, Daniela
    Thamer, Claus
    Schoelch, Corinna
    Desch, Michael
    Hennige, Anita M.
    DIABETES OBESITY & METABOLISM, 2023, 25 (04): : 1011 - 1023
  • [9] Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist
    Parker, Victoria E. R.
    Robertson, Darren
    Wang, Tao
    Hornigold, David C.
    Petrone, Marcella
    Cooper, Aidan T.
    Posch, Maximilian G.
    Heise, Tim
    Plum-Moerschel, Leona
    Schlichthaar, Heike
    Klaus, Beate
    Ambery, Philip D.
    Meier, Juris J.
    Hirshberg, Boaz
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (03): : 803 - 820
  • [10] A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness
    Beinborn, M
    Worrall, CI
    McBride, EW
    Kopin, AS
    REGULATORY PEPTIDES, 2005, 130 (1-2) : 1 - 6
12345